Premium
Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy
Author(s) -
Huang ChinWei,
Pai MingChyi,
Tsai JingJane
Publication year - 2008
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/j.1440-1819.2008.01848.x
Subject(s) - levetiracetam , topiramate , cognition , epilepsy , lamotrigine , psychology , medicine , randomized controlled trial , effects of sleep deprivation on cognitive performance , psychiatry
Aim: Anti‐epileptic drugs (AED) may cause cognitive impairment. Because intractable epilepsy (IE) represents a distinct group, the purpose of the present study was to study the comparative cognitive effects of the two efficacious AED, levetiracetam (LEV) and topiramate (TPM), on IE. Methods: This was a non‐randomized, blinded cognitive assessment and parallel design. The cognitive effects of LEV and TPM on 79 demographically comparable patients with IE were assessed at baseline (T1) and after 1 year of treatment (T2) using the Cognitive Abilities Screening Instrument. Results: Forty patients took TPM and 39 took LEV. At T1, seizure frequency, number of AED, and epilepsy duration were not significantly different. There were no significant differences in cognition between the two groups at T1 or T2. T2 orientation scores were lower than T1 scores in the TPM group ( P < 0.05). In the TPM subgroup with T1 cognitive abnormalities, T2 scores for recent memory improved ( P < 0.05). Conclusion: For patients with IE, LEV might preserve cognition, TPM's effects for patients with baseline cognitive abnormalities are worth observation.